Group items tagged

It's a fact that loss of sexual desire or low libido strains a marriage more than any other cause. According to studies, it troubles 15-16% of men and about twice that of men women are affected. Men boost of their supremacy and masculinity in their world. Loss of interest in sex make men more nervous than women. Due to the loss in appetite for sex they are unhappy and petrified in their lives.

Global drug discovery services market will continue to grow, owing to upsurge in externalization of R&D activities, rising expenditure on R&D, and increasing incidence of chronic diseases. Expiration of patents boosting the demand for drug discovery and the introduction of innovative drug discovery technologies are projected to support the market growth during the forecast period 2019-2025. The global drug discovery services market, by type, is segmented into medicinal chemistry services, biology services, and pharmacokinetics and drug metabolism. Among these, the medicinal chemistry services segment accounted for the largest share in 2018 and is expected to grow at a high-double-digit CAGR by 2025. Increasing tendency of pharma companies to externalize discovery & development services, upsurge in the number of drug discovery & development activities, and growing R&D expenditure are the key factors driving the growth of the segment.

As the government today (November 15) announced plans to expand Britain's booster programme for Covid-19 vaccinations to cover all adults aged over 40, NHS Confederation welcomed the move. The announcement follows the Joint Committee on Vaccination and Immunisation (JCVI) statement that all healthy adults aged 40-49 should be offered a booster, six months after their second dose, and that 16 and 17 year olds should be invited to have a second dose. Accepting the JCVI's advice, health and social care secretary Sajid Javid said: "All 4 parts of the UK intend to follow the JCVI's advice. "We know immunity to Covid-19 begins to wane after 6 months and new data published today shows a third dose boosts protection against symptomatic infection to more than 90% - this highlights just how important it is that everyone eligible gets their top-up jabs as soon as possible."

Solgar® is delighted to announce the launch of its newest innovation Solgar®Earth Source® Koji Iron 27mg. The new supplement is designed to support consumers' everyday energy levels and uses an innovative koji fermentation process to transform mineral iron into an iron-rich fermented food which is high in bioavailability,easy to absorb and gentle on the stomach. Available now in a 30-capsule bottle (Trade Price £6.50 - RRP £13.99/€14.50), each capsule will provide 27mg of naturally sourced koji food fermented iron. The convenient one-a-day formulation offers a number of health benefits including: Supporting energy and reducing tiredness and fatigue Contributing to the formation of haemoglobin and red blood cells Supporting cognition Supporting immune defences Minerals, including iron, support growth and development and ensure our bodies function optimally. Iron is present mostly in animal protein such as lean meats and seafood, but also in nuts, tofu and white beans in smaller amounts. Iron supports the production of haemoglobin, the crimson pigment in red blood cells, that helps carry oxygen around the body. It also helps energise the body, and athletes, for example, may need more iron to support oxygen transport to muscles so they can keep exercising.

As part of community service in our pharmacies we provide advice, help and support on the importance of a varied and balanced diet and a healthy lifestyle. This has been especially important during the Covid-19 pandemic as many of our customers are understandably even more concerned about their immune health and how they can help boost their immunity during this time in order to protect themselves as far as possible. We help them understand the relevance of good nutrition, the importance doing exercise (where possible), and how they can take steps to reduce risk over these worrying times. For example, through our pharmacy services, we offer the flu jab to customers and support the NHS in administering the jab, for which demand has been greatly increased this year as people look to protect their immune system from flu (which for some - can prove fatal). By protecting from illness, our body's immune system can remain stronger, as is not distracted into fighting illnesses that could have been prevented.

Around 90 percent of coronavirus patients in intensive care units have not had a booster jab, prime minister Boris Johnson said on Wednesday (December 29) - defending his decision not to tighten virus curbs in England. Speaking at a vaccination centre, Johnson urged people to get "vital" booster jabs, saying "the overwhelming majority" of those currently going into intensive care in our hospitals have not had the booster jab. "I've talked to doctors who say the numbers are running up to 90 percent of people in intensive care who are not boosted," the prime minister added in Milton Keynes in Hertfordshire. Those who have not been vaccinated are "eight times more likely to get into hospital," he warned. The UK has been hit by a huge surge of the new Omicron variant, with England and Wales reporting record case numbers on Tuesday. The UK has been one of Europe's worst hit with a death toll of 148,021.

A pioneering study by UCL researchers has found that just three minutes of exposure to deep red light once a week, when delivered in the morning, can significantly improve declining eyesight. Published in the journal Scientific Reports, the study builds on the team's previous work, which showed daily three-minute exposure to longwave deep red light 'switched on' energy-producing mitochondria cells in the human retina, helping boost naturally declining vision. For this latest study, scientists wanted to establish what effect a single three-minute exposure would have, while also using much lower energy levels than their previous studies. Furthermore, building on separate UCL research in flies that found mitochondria display 'shifting workloads' depending on the time of day, the team compared morning exposure to afternoon exposure.

Trying to lose weight? To boost your dieting mission, we have crafted the list of 6 essential nutrients that help you to lose extra fats & calories effectively.

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

Following discussions with Community Pharmacy Scotland, the Scottish government has agreed to a six per cent rise in the global fund allocation for community pharmacies in 2023-24, bringing the total remuneration to approximately £219.5 million. A finalised agreement has been reached with Community Pharmacy Scotland for a one-year funding package for the financial year 2023-24, as stated in a Scottish government circular distributed to community pharmacy contractors and NHS Boards on August 4. The circular said this settlement will lead to the most substantial increment ever approved for the community pharmacy network. "The global sum remuneration will be £219.533 million, signifying a 6 per cent increase from the previous year and setting the groundwork for 2024/25," stated Professor Alison Strath, Chief Pharmaceutical Officer for Scotland, in the document. "The guaranteed income from the drug tariff will remain at £80 million for the financial year, without yearly changes."

The government has launched a consultation into radically changing the Statutory Scheme for branded medicines (known as the Statutory Scheme). The consultation comes as delicate negotiations for replacing the alternative Voluntary Scheme are underway, potentially undermining these talks, while also further damaging industry confidence in the UK as a viable place to research, launch and supply medicine. The government proposals seek to hold average revenue clawback rates under the Statutory Scheme at historic highs of between 21-27%, compared to the pre-pandemic averages of 9.4% for the Statutory Scheme (2019-2021), and 6.88% for the Voluntary Scheme (2014-2021). The accompanying cost-benefit analysis ignores any negative impact this may have on medicine supply and wrongly claims it will boost investment. The consultation comes on the heels of government data last week showing UK life sciences foreign direct investment (FDI) fell by 47% between 2021 and 2022, down by £900m year on year. This large fall in investment coincided with a rise in the main UK clawback rate under the Voluntary Scheme from 5% to 15%, and led to the UK falling from 2nd to 9th out of 18 comparator countries for life sciences FDI in 2022. The Voluntary Scheme clawback rate now sits at a record 26.5% in 2023.

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document published by Nuffield Trust and The King's Fund has revealed. It says community pharmacies in England must adapt to changing population needs amidst unprecedented health and care challenges. Commissioned by Community Pharmacy England, the report titled 'A Vision for Community Pharmacy', published on Sept. 19, is a result of almost a year of research and extensive consultation with the sector and wider stakeholders, advocating for community pharmacy. The think tanks detail a shift in the community pharmacy sector, highlighting how pharmacies can contribute to crucial policy objectives regarding population health, prevention, and the increasing demand in primary care. "The health and care needs of the population are evolving, and pharmacies in England, like all components of the health and care system, must adjust to address these changes," said Helen Buckingham, Director of Strategy at Nuffield Trust.

Winter is imminent and with dropping temperatures viruses are bound to be more prevalent, exacerbating health problems among the vulnerable and immunocompromised patients. This can cause serious complications, and therefore, it's important to know the symptoms, methods to manage them and when to refer. A healthy person can usually manage the illnesses with over-the counter medication. Colds, flu and Covid-19 are caused by different viruses. As some of their symptoms overlap, it may be hard to tell the difference. However, some key differences are shown in the following figure. It is also possible to suffer from cold/flu and Covid-19 simultaneously, which can complicate matters. As per NHS guidelines, anyone with fever, cough, loss/change in sense of taste and/or smell has to self-isolate and request a Covid test. Pharmacy Advice The pharmacy team should advise patients with symptoms to take rest, ensure adequate hydration and take balanced nutrition. Supplements such as Vitamin C, Vitamin D and zinc can also help to boost the immune system and can be recommended.

Living in challenging times means that the world seems to be constantly changing, and it can be hard to keep up. Along with all the other challenges you face, it's more important than ever to stay healthy. But what does that mean for you? What are the health tips that everyone should follow? There's a lot of information out there about health and wellness, and it can be overwhelming trying to figure out what's best. That's why you should check this list of the top seven health tips that everyone should follow. GET REGULAR EXERCISE Everyone needs to make time for physical activity and aim for at least 150 minutes of moderate-intensity exercise each week. This can be anything from walking or swimming to dancing or aerobics classes. Exercise not only strengthens your body, but it can also help you manage stress and improve your mood, while also boosting your immune system. If, for any reason, you're not able to get the recommended amount of exercise, try breaking up activities into smaller chunks and incorporating them into your daily routine.

Pharmaceutical giant AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday (November 29) as it seeks to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead. "Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years," said Susan Galbraith, AstraZeneca's executive vice president of oncology research. Cell-based treatments are a relatively new approach to treating cancer, most of which involve drawing the body's own immune cells and processing them in the lab to target and kill cancer cells. Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain proteins on the surface of cancer cells.

The Health Committee's new report has reminded the government of a much-needed pharmacy workforce plan to support recruitment, training, and retention of staff. The report makes a number of recommendations to optimise workloads across primary care, reduce pressure on general practice and hospitals, and support the integrated care systems. It also recognises the potential of pharmacist independent prescribers to support patient care, backed by appropriate supervision, training, and opportunities for professional development. RPS England gave evidence to MPs on the Committee at a public hearing in May, highlighting key issues to support the pharmacy workforce. RPS director for England, Ravi Sharma, said: "Today's report underlines the urgent need for the Government to set out a comprehensive workforce plan for health and care. "It rightly recognises that boosting recruitment and retention, supporting staff wellbeing, fostering inclusion and diversity, and investing in education and training will be crucial to the future of the NHS.

New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer health division Haleon. After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of strong results. The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy. Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain around U.S. litigation over heartburn drug Zantac. Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.

The opinions of pharmacists on the ketogenic diet can vary greatly. Some believe that it is a potentially effective and safe way to lose weight, while others are more skeptical about its ability to promote sustainable health benefits over the long term. Ultimately, the success of the ketogenic diet will depend on each individual's unique circumstances and personal goals, so it is important to consult with a medical professional before making any major changes to your diet or lifestyle. 1. KETO DIET IS CONSIDERED A GOOD WAY TO LOSE WEIGHT Some people find that the ketogenic diet can boost their energy levels and help them lose weight quickly, while others feel that they are more easily able to stick to this diet as it allows them to eat a wider variety of foods. Many people find that the ketogenic way of eating prevents cravings and helps them avoid unhealthy food choices, which can be an important factor in weight loss success. So if you are starting your ketogenic diet journey, it is important to seek out the advice of a medical professional who can help you create an individualized plan that will support your specific goals. It's also important to track your progress regularly and monitor how you are feeling so that you can make any necessary adjustments along the way.

Immunogenicity refers to the capacity of a vaccine to provoke an immune response in the body. An effective immune response is characterized by the production of specific antibodies, activation of immune cells, and the development of immunological memory. The goal is to elicit a durable and robust response that can prevent or control infections. Leveraging Viral Vector Technology Viral vectors serve as essential vehicles for delivering antigenic proteins or genetic material into target cells, triggering an immune response. Biotechnology companies have been exploring advanced strategies to optimize viral vector design, aiming to enhance immunogenicity and improve vaccine effectiveness. Vector Selection: The choice of viral vector plays a crucial role in determining immunogenicity. Different viruses have unique properties and characteristics that can impact immune responses. Biotechnology companies meticulously select viral vectors that possess the desired attributes, such as the ability to infect target cells efficiently and induce strong immune responses. Genetic Engineering: Advanced genetic engineering techniques are employed to modify viral vectors, tailoring them to specific vaccine requirements. By introducing specific antigenic proteins or genetic material, researchers can stimulate the immune system to mount a targeted response. This precise manipulation enhances the vaccine's ability to elicit a robust immune reaction. Immunomodulatory Elements: Biotechnology companies are incorporating immunomodulatory elements into viral vector designs. These elements can enhance the immune response by stimulating various components of the immune system, such as antigen-presenting cells and T cells. By activating and priming these immune cells, the vaccine can generate a more potent and sustained immune response. Adjuvants: Adjuvants are substances added to vaccines to enhance their immunogenicity. They stimulate and amplify the immune response, improving the va